Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Adc Therapeutics SA (NYSE: ADCT) closed the day trading at $3.95 down -14.13% from the previous closing price of $4.6. In other words, the price has decreased by -$14.13 from its previous closing price. On the day, 11.54 million shares were traded. ADCT stock price reached its highest trading level at $4.55 during the session, while it also had its lowest trading level at $2.94.
Ratios:
For a better understanding of ADCT, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.34 and its Current Ratio is at 4.63.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on November 08, 2024, initiated with a Overweight rating and assigned the stock a target price of $6.
On March 28, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $11.Guggenheim initiated its Buy rating on March 28, 2024, with a $11 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’24 when Redmile Group, LLC bought 100,000 shares for $3.04 per share. The transaction valued at 304,500 led to the insider holds 15,666,731 shares of the business.
Redmile Group, LLC bought 100,000 shares of ADCT for $304,500 on Dec 11 ’24. The 10% Owner now owns 13,145,712 shares after completing the transaction at $3.04 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADCT now has a Market Capitalization of 489314592 and an Enterprise Value of 712012608. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.51. Its current Enterprise Value per Revenue stands at 9.467 whereas that against EBITDA is -5.86.
Stock Price History:
The Beta on a monthly basis for ADCT is 1.93, which has changed by 1.3958333 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, ADCT has reached a high of $4.80, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is -5.10%, while the 200-Day Moving Average is calculated to be 38.54%.
Shares Statistics:
Over the past 3-months, ADCT traded about 891.51K shares per day on average, while over the past 10 days, ADCT traded about 754040 shares per day. A total of 112.63M shares are outstanding, with a floating share count of 99.31M. Insiders hold about 19.84% of the company’s shares, while institutions hold 52.66% stake in the company. Shares short for ADCT as of 1763078400 were 5867155 with a Short Ratio of 6.58, compared to 1760486400 on 6374485. Therefore, it implies a Short% of Shares Outstanding of 5867155 and a Short% of Float of 5.72.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Adc Therapeutics SA (ADCT) in the stock market.The consensus estimate for the next quarter is -$0.28, with high estimates of -$0.26 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$1.34 and -$1.48 for the fiscal current year, implying an average EPS of -$1.41. EPS for the following year is -$1.11, with 6.0 analysts recommending between -$0.84 and -$1.33.
Revenue Estimates
6 analysts predict $18.33M in revenue for. The current quarter. It ranges from a high estimate of $19.3M to a low estimate of $17.48M. As of. The current estimate, Adc Therapeutics SA’s year-ago sales were $16.91MFor the next quarter, 6 analysts are estimating revenue of $19.65M. There is a high estimate of $20.6M for the next quarter, whereas the lowest estimate is $18.7M.
A total of 6 analysts have provided revenue estimates for ADCT’s current fiscal year. The highest revenue estimate was $77.6M, while the lowest revenue estimate was $75.77M, resulting in an average revenue estimate of $76.65M. In the same quarter a year ago, actual revenue was $70.84MBased on 6 analysts’ estimates, the company’s revenue will be $79.61M in the next fiscal year. The high estimate is $92M and the low estimate is $69.2M.
